Merck & Company Receives Buy Rating from J.P. Morgan with $120 Price Target
ByAinvest
Friday, Aug 1, 2025 9:19 am ET1min read
MRK--
Technical analysis provides a mixed picture. Several analysts have noted that MRK is trading in a downtrend, with key support levels around $80 and resistance levels at $90 and $92. A recent breakdown below $94.23 suggests further downside pressure. However, some analysts see potential for a short-term rebound, with key resistance at $94.00 and a possible long-term reversal if the stock breaks above $100-$105.
Long-term traders are also considering Merck as an accumulation zone for long-term positions, with targets set at $110 and $124.65, representing potential 27% and 47% upside from the current price, respectively. Patience is advised, with a focus on establishing a firm bottom around $90-$95 and waiting for confirmation of reversal via technical indicators or bullish news catalysts.
In summary, while Merck faces a bearish bias in the short term, long-term investors see potential for a significant upside if the stock can break through key resistance levels. Analyst ratings provide a mixed outlook, with J.P. Morgan and TR | OpenAI – 4o’s Veda Pharmyne bullish, while Wells Fargo is cautious.
References:
[1] https://www.tradingview.com/symbols/TURQUOISE-MRKN/ideas/page-2/
[2] https://www.tradingview.com/symbols/TURQUOISE-MRKN/ideas/page-2/
WFC--
J.P. Morgan analyst Chris Schott maintained a Buy rating on Merck & Company with a price target of $120.00. The company received a similar rating from TR | OpenAI – 4o’s Veda Pharmyne, but Wells Fargo maintained a Hold rating. Merck & Company has a one-year high of $120.30 and a one-year low of $73.31, with an average volume of 15.16M.
Merck & Co. (MRK) has been the subject of varied analyst ratings, with J.P. Morgan's Chris Schott maintaining a Buy rating with a price target of $120.00. This rating is echoed by TR | OpenAI – 4o’s Veda Pharmyne, while Wells Fargo holds a Hold rating. The stock has seen significant volatility, with a one-year high of $120.30 and a one-year low of $73.31, and an average daily trading volume of 15.16 million shares.Technical analysis provides a mixed picture. Several analysts have noted that MRK is trading in a downtrend, with key support levels around $80 and resistance levels at $90 and $92. A recent breakdown below $94.23 suggests further downside pressure. However, some analysts see potential for a short-term rebound, with key resistance at $94.00 and a possible long-term reversal if the stock breaks above $100-$105.
Long-term traders are also considering Merck as an accumulation zone for long-term positions, with targets set at $110 and $124.65, representing potential 27% and 47% upside from the current price, respectively. Patience is advised, with a focus on establishing a firm bottom around $90-$95 and waiting for confirmation of reversal via technical indicators or bullish news catalysts.
In summary, while Merck faces a bearish bias in the short term, long-term investors see potential for a significant upside if the stock can break through key resistance levels. Analyst ratings provide a mixed outlook, with J.P. Morgan and TR | OpenAI – 4o’s Veda Pharmyne bullish, while Wells Fargo is cautious.
References:
[1] https://www.tradingview.com/symbols/TURQUOISE-MRKN/ideas/page-2/
[2] https://www.tradingview.com/symbols/TURQUOISE-MRKN/ideas/page-2/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet